Innate’s first NK cell engager selected by Sanofi as drug candidate for development

Marseille, Jan. 05, 2021 (GLOBE NEWSWIRE) — IPH6101/SAR443579 is an NKp46-based NK cell engager (NKCE) that uses Innate’s proprietary multispecific antibody format Selection of IPH6101/SAR443579 triggers a €7M milestone payment to Innate Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that Sanofi has made the decision […]

Continue Reading

Innate’s First NK Cell Engager Selected by Sanofi as Drug Candidate for Development

IPH6101/SAR443579 is an NKp46-based NK cell engager (NKCE) that uses Innate’s proprietary multispecific antibody format Selection of IPH6101/SAR443579 triggers a €7M milestone payment to Innate MARSEILLE, France, Jan. 05, 2021 (GLOBE NEWSWIRE) — Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that Sanofi has made the […]

Continue Reading

Innate Pharma to Participate in Upcoming Investor Conferences

MARSEILLE, France, Jan. 04, 2021 (GLOBE NEWSWIRE) — Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“Innate” or the “Company”) announced today that members of its senior management team are scheduled to participate in the following upcoming virtual investor conferences. ODDO BHF Digital ForumDate: January 7-11, 2021 SternIR Virtual Corporate Access EventDate: […]

Continue Reading

Innate Pharma to Participate in Upcoming Investor Conferences

MARSEILLE, France, Jan. 04, 2021 (GLOBE NEWSWIRE) — Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“Innate” or the “Company”) announced today that members of its senior management team are scheduled to participate in the following upcoming virtual investor conferences. ODDO BHF Digital ForumDate: January 7-11, 2021 SternIR Virtual Corporate Access EventDate: […]

Continue Reading

Innate Pharma to participate in upcoming investor conferences

Marseille, Jan. 04, 2021 (GLOBE NEWSWIRE) — Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“Innate” or the “Company”) announced today that members of its senior management team are scheduled to participate in the following upcoming virtual investor conferences.       ·ODDO BHF Digital ForumDate: January 7-11, 2021       ·SternIR Virtual Corporate Access EventDate: January […]

Continue Reading

Innate Pharma to participate in upcoming investor conferences

Marseille, Jan. 04, 2021 (GLOBE NEWSWIRE) — Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“Innate” or the “Company”) announced today that members of its senior management team are scheduled to participate in the following upcoming virtual investor conferences.       ·ODDO BHF Digital ForumDate: January 7-11, 2021       ·SternIR Virtual Corporate Access EventDate: January […]

Continue Reading

 Innate Pharma to return US and EU Lumoxiti commercialization rights to AstraZeneca

Marseille, Dec. 11, 2020 (GLOBE NEWSWIRE) — Innate will no longer pursue Lumoxiti commercialization activities in US or EU; Company to re-focus investments in its R&D portfolio   Companies will develop a transition plan with the goal of returning full commercialization responsibilities to AstraZeneca in 2021  Companies will ensure availability of Lumoxiti to patients during transition […]

Continue Reading

Innate Pharma to Return US and EU Lumoxiti Commercialization Rights to AstraZeneca

Innate will no longer pursue Lumoxiti commercialization activities in US or EU; Company to re-focus investments in its R&D portfolio  Companies will develop a transition plan with the goal of returning full commercialization responsibilities to AstraZeneca in 2021 Companies will ensure availability of Lumoxiti to patients during transition period Conference call to be held today […]

Continue Reading

 Innate Pharma to present additional efficacy data for monalizumab in combination with cetuximab in head and neck cancer at the ESMO immuno-oncology virtual congress

Phase 2 expansion cohort data supports ongoing Phase 3 trial Marseille, Dec. 03, 2020 (GLOBE NEWSWIRE) — Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that it will present additional data on its lead partnered asset, monalizumab, at the ESMO Immuno-oncology Virtual Congress being held from […]

Continue Reading

Innate Pharma to Present Additional Efficacy Data for Monalizumab in Combination With Cetuximab in Head and Neck Cancer at the ESMO Immuno-Oncology Virtual Congress

Phase 2 expansion cohort data supports ongoing Phase 3 trial MARSEILLE, France, Dec. 03, 2020 (GLOBE NEWSWIRE) — Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that it will present additional data on its lead partnered asset, monalizumab, at the ESMO Immuno-oncology Virtual Congress being held […]

Continue Reading